Exposure to flaxseed or purified lignan during lactation influences rat mammary gland structures.
Previous investigation demonstrated that feeding a 10% flaxseed (10F) diet during pregnancy and lactation enhanced the differentiation of highly proliferative terminal end bud (TEB) structures of rat mammary gland into less proliferative alveolar buds and lobules. From this study, it was hypothesized that the lignan component in flaxseed mediated the observed effects. Because mammary glands with more TEBs are more susceptible to carcinogens, exposure to flaxseed during early postnatal life may reduce the risk of developing mammary cancer. Our objectives were to elucidate whether exposure to flaxseed during lactation only and during pregnancy and lactation can similarly influence the differentiation of mammary gland structures and also to identify whether the lignan component of flaxseed is the biologically active agent. Offspring were exposed to a 10F diet or a dose of purified lignan equivalent to that in a 10F diet (10S) during lactation only or from lactation to postnatal Day 50. Compared with controls, exposure to 10F or 10S during lactation only or from lactation to postnatal Day 50 reduced the number of TEBs and resulted in a rise in the number of alveolar buds. In conclusion, exposure to flaxseed or its purified lignan during lactation is a critical period in which mammary gland development may be promoted by enhancing the differentiation of the mammary gland structures. However, continuous exposure, particularly to purified lignans, resulted in the most differentiation of the mammary gland. The next step is to determine whether the changes in mammary gland structures are chemopreventive in rats challenged with a carcinogen.
Ward
W E
WE
Department of Nutritional Sciences, University of Toronto, Toronto, ON, Canada M5S 3E2.
Jiang
F O
FO
Thompson
L U
LU
D000704:Analysis of Variance; D000818:Animals; D016588:Anticarcinogenic Agents / Q000494:pharmacology*; D002072:Butylene Glycols / Q000008:administration & dosage / Q000494:pharmacology*; D005260:Female; D019597:Flax / Q000737:chemistry; D005960:Glucosides / Q000008:administration & dosage / Q000494:pharmacology*; D007774:Lactation / Q000187:drug effects*; D017705:Lignans / Q000494:pharmacology*; D008321:Mammary Glands, Animal / Q000033:anatomy & histology / Q000187:drug effects*; D015674:Mammary Neoplasms, Animal / Q000517:prevention & control; D011247:Pregnancy; D011897:Random Allocation; D051381:Rats
D016588:Anticarcinogenic Agents; D002072:Butylene Glycols; D005960:Glucosides; D017705:Lignans; C090142:secoisolariciresinol diglucoside